Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary ...
The AHA and ACC issued a guideline on a clinical classification system to define the severity of an acute PE and assist in developing treatment strategies.